

References

- Abd Rabbo SA (1994):** Stepwise uterine devascularization: a novel technique for management of uncontrolled PPH with preservation of the uterus. *Am J Obstet Gynecol* Sep; 171 (3): 694-700.
- Abouzahr C (1998):** Antepartum and postpartum hemorrhage. In: Murray CJ, Lopez AD, eds. *Health Dimension and Reproduction*. Boston, Man: Harvard University press; 172-4.
- Acalovschi M, Dumitrascu DL, Suteu T, Veres A, Albu S and Badea RL, (2002):** Acute intravaginal misoprostol toxicity with fetal demise, *Acta Gastroenterol Belg*, 65: 191.
- Acharya G, Al-Sammarai MT, Patel N, Al-Habib A and Kiserad T, (2001):** A randomized controlled trial comparing effect of oral misoprostol and intravenous syntocinon on intraoperative blood loss during cesarean section. *Acta Obstet Gynecol Scand*; 80 (3): 245-50.
- ACOG Committee Opinion 283(2003):** New US FDA Labelling on Cytotec (Misoprostol) use and pregnancy.
- ACOG Technical Bulletin 157(1991):** Induction and augmentation of labor.
- Adekamni OA, Purmessur S and Edwards G, (2001):** Intrauterine misoprostol for treatment of severe recurrent atonic secondary postpartum hemorrhage. *Br. J. Obstet Gynecol*; 108: 541-542.
- Akhter S, Begum MR, Kabir Z, et al., (2003):** Use of a condom to control massive postpartum hemorrhage. *Med Gen Med* 11; 5(3): 38.
- Alamia V Jr, Meyer BA.(1999):** Peripartum hemorrhage. *Obstet Gynecol Clin North Am*; 26: 385-98.
- American Academy of Pediatrics, American College of Obstetricians and Gynecologists (1997):** Guidelines for perinatal care. 4th ed. ELK Grove Village, III, American Academy of Pediatrics.
- American College of Obstetricians and Gynecologists (1989):** Quality assurance in obstetrics and gynecology. Washington, DC: ACOG.
- American College of Obstetricians and Gynecologists (1998):** Postpartum hemorrhage. ACOG Educational Bulletin No243 Washington, DC; the college.
- American College of obstetricians and Gynecologists (2003):** Induction of labor with misoprostol ACOG committee opinion 228 Washington DC: ACOG: 1999.
- Anthony A, Bamigboy S, Hofmeyer, and Merrel D (1998):** Rectal administration of misoprostol in the prevention of postpartum hemorrhage: A placebo controlled trial. *Am J Obstet Gynecol*; 1043-46.
- Ashok PW, Templeton A (1999):** Non surgical mid-trimester termination of pregnancy: a review of 500 consecutive cases. *BJOG*, volume 106 , Issue, 7, P 706-710.
- Atoyebi W, Mundy N, Croxton T, et al., (2000):** Is it necessary to administer ant-D to prevent Rh-Immunization after the transfusion of Rh-D-positive platelet concentrates? *Br J Haematol*, III (3): 980-3.

- Aubeny E and Baulieu (1991):** Active contragestive de l'association au RU, 486d'une prostaglandin active par voie oral. CR Acad Sci. (III): 312: 539 Quoted in El-Refaey H.
- Austin JF, Rouse A and Hanna E (1997):** Acute intravaginal misoprostol toxicity with fetal demise J. of emergency med 15 (1): 61-64.
- Babinszki A, Kerenyi T, Torok O, Grazi V, Labiniski RH, and Berkowitz RL (1999):** Perinatal outcome in grand and great-grand multiparity. Am J Obstet Gynecol, 181:669.
- Bamigboye AA, Hofmyer G, Merrel DA (1998):** Rectal misoprostol in the prevention of postpartum hemorrhage. Am J Obstet Gynecol, 179: 1043-6.
- Barbosa R and Ariha M (1993):** The Brazilian experience with cytotec. Stud. Fam Plans; 24: 236.
- Baskett TF (1999):** Complications of the third stage of labor. In: Essential Management of Obstetrical Emergencies 3rd. Bristol, England: Clinical Press, 196-201.
- Begley CM (1990):** A comparison of active and physiological management of third stage of labor. Midwifery; 6 (1): 3-17.
- Bennet LZ, Krotez DL, Sheiner LB (1996):** Pharmacokinetics: The dynamics of drug absorption, distribution and elimination. In Hardman JG, Gilman AG, Limbird LE, editors, Goodman and Gilman: the pharmacological basis of therapeutics. 9th Ed. New York: MC Graw-Hill; P. 3-27.
- Bennet PN, Fenn GC, Notarianni LJ (1988):** Potential drug interaction with misoprostol: Effects on the pharmacokinetics of antipyrine and propranolol. Postgrad Med. J.; 64 (suppli): 21-4.
- Bennett BB. (1997):** Uterine rupture during induction of labor at term with intravaginal misoprostol obstet Gynecol, 89: 832-3.
- Bjorenerem A, Acharya G, Oian, P, Maltan M, (2002):** Postpartum hemorrhage prophylaxis and treatment in Norway. Tidsskr Nor Laege foren; 122 (26): 2556-7.
- Blanco JD and Finely BF (1987):** Induction and stimulation of labor. Clinical Obstetrics Care J. Paurestein, 1st ed. John Wiley and Sons Inc: 495.
- B-Lynch C, Cocker A, Lawal AH, et al., (1997):** The B-Lynch surgical technique for the control of massive postpartum hemorrhage an alternative to hysterectomy? Five cases reported. Br J Obstet Gynecol, 104 (3): 372-5.
- Bonner J (2000):** Massive obstetric hemorrhage. Baillieres Best Pract Res Clin Obstet Gynecol; 14(1): 1-18.
- Bowman EA, Barclay DL, White LC (1964):** Cesarean hysterectomy: an analysis of 1000 consecutive operations. Bull Tulane Med Faculty; 23-75.
- Braf ZF, Knootz WW (1979):** Gangrene of bladder. Complications of hypogastric artery embolization. Urology; 9:670.
- Bruce SL, Paul RH and Van Dorsten JP (1982):** Control of postpartum uterine atony by intramyometrial prostaglandin. Obstet Gynecol; 59: 47.
- Bugalho A, Bigne C, Percira C, Granja AC and Bergstrom S (1995):** Uterine contraction by vaginal misoprostol after second trimester pregnancy. Interruption. Acta Obstet Gynecol. Second; 75: 270-273.
-
-

- Bullongh CH, Msuku RS, Karonde L (1989):** Early suckling and postpartum hemorrhage: Controlled trial in deliveries by traditional birth attendants. *Lancet* Sep 2; 2 (8662): 522-5.
- Burcell RC (1968):** Physiology of internal iliac artery ligation. *J Obstet Gynecol Br Commonw*; 75: 642.
- C.S. Todd M Soler L, Castleman M.K. Rogers and P.D. Blumenthal (2002):** Buccal misoprostol as cervical preparation for second trimester pregnancy termination. *Contraception* 65, pp. 415-418.
- Cabanac M, Pfaff DW, Ogawa S (1999):** Neural oxytocinergic systems as genomic targets for hormones. *Results Probl Cell Differ*; 26:91.
- Calder A and Embry M. (1973):** Prostaglandins and unfavorable cervix. *Lancet*; 2: 1322.
- Calder AA (1990):** Pharmacological management of the unripe cervix in the human. In Naftolin F and Stubble field PG: *Dilatation of the uterine cervix*. Raven. Press, New York; pp 317.
- Calder AA, Embrey MP (1975):** In Beard RW, Brudenell M and Dunn P. et al (eds). *The management of labor. Proceeding of the third RCOG study group*. Royal College of Obstetricians and Gynecologists, P. 64.
- Caliskan E, Meydanli M, Dilbaz B, Ay Kan B, Sonmezer M and Hoberal A (2002):** Is rectal misoprostol really effective in the treatment of third stage of labor? A randomized controlled trial. *Am J Obstet Gynecol*, 187: 1038-45.
- Callen PJ, De Louvois J, Hurley R et al., (1980):** Intrapartum and postpartum pyrexia and infection after induction with extra-amniotic PGE2 in tylose. *Br. J. Obstet Gynecol* 87, 513-518.
- Campbell, R.Gipson, A.H.Issa, N.Matta, B.El Deeb and A.El Mohandes, et al., (2005):** National maternal mortality ratio in Egypt halved between 1992-1993 and 2000, *Bull World health* 83 (6): 462-471.
- Carbonell JL, Velazco A and Rodriguez Y et al., (2001):** Oral versus vaginal misoprostol for cervical priming in first-trimester abortion: a randomized trial. *Eur Contracept Reprod Health Care* (6), pp 134-140.
- Carlan S.J.MD; Blust, Danielle MD; O'Brien Whilliam E (2002):** Buccal versus intravaginal misoprostol for cervical ripening. *Am. J. Obstet Gynecol*. Volume. 66 (2): pp. 229-233.
- Carlan SJ, Blust D, O'Brien WF (2002):** Buccal misoprostol administration for cervical ripening. *Am J Obstet Gynecol*; 186: 229-33.
- Carroli G, Belizan J (1999):** Episiotomy for vaginal birth *Cochrane data System Rev*; (3): CD000081.
- Carroli G, Bergel E (2004):** Umbilical vein injection for management of retained placenta (Cochrane Review); In: *The Cochrane library*, issue 3,. Chichester, UK: John Wiley & Sons, Ltd,
- Casey ML, Mac Donald PC (1997):** The endocrinology of human parturition. *Ann NY Acad Sci* 828: 273.
- Celik H and Sapmaz E (2003):** Use of a single preoperative dose of misoprostol is efficacious for patients who undergo abdominal myomectomy. *University of Firat (Euphrates), Faculty of Medicine, Departments of Obstet Gynecol, Elazig, Turkey. Fertile Steril* 79 (5): 1207-10.
-
-

- Christopher AE, Imran OM, Evbu OE, Ayodele OA, and Akinyinka OO (2007):** Oral misoprostol during the third stage of labor. *The Journal of Obstetric and Gynecologic Research*, Vol 33(6), p 810-817.
- Chung TKH, Cheung LP, Leung TY, Haines CJ and Chang AMZ (1995):** Misoprostol in the management of spontaneous abortion. *BJOG*; 102: 832-835.
- Cines DB, Blanchette VS (2002):** Immune thrombocytopenic purpura. *N. Engle. J. Med* 346 (31): 995-1008.
- Cines DB, Bussel JB (2005):** How to treat idiopathic thrombocytopenic purpura 106 (7): 2744-51.
- Clark S, Blum J, Blanchard K, Galvo et al., (2002):** Misoprostol use in obstetrics and gynecology in Brazil, Jamaica and the United States. *Am J. Obstet Gynecol* 76: 65-74.
- Clark SL, Koonings P, Phelan JP (1985):** Placenta accrete and previous cesarean section. *Obstet Gynecol*, 66-89.
- Clark SL, Yeh S-Y, Phelan JP, et al., (1984):** Emergency hysterectomy for the control of obstetric hemorrhage. *Obstet Gynecol* 1984; 64: 376.
- Coelho HI, Teixeira A, Santos A, Forte E, Morial S Vecchia C, Tognoni G and Herxheimer A (1993):** Misoprostol and illegal abortion in Brazil. *The lancet* 341:1261-3.
- Coleman RA, and Sheldrick RL (1989):** Prostanoid induced contraction of human bronchial smooth muscle is mediated by Tp-receptors. *Br. J. Pharmacol*; 96: 688-692. Quoted from Coleman R.A., Smith WL and Narumiya S (1994): Classification of prostanoid receptors. *Pharmacol Rev.* 1994, 46; 205-229.
- Coleman RA, Smith WL and Narumiya S. (1994):** International union of pharmacology classification of prostanoid receptors. *Pharmacol Rev*, 46: 205-229.
- Collins P.W.; Dajani EZ and Pappo R. (1983):** Discovery of misoprostol. *J. Med. Chem.* 26, 786.
- Collins PW (1990):** Misoprostol discovery development and Clinical application *Contraception*, 53: 321-7.
- Cook CS, Schoehard GL, Karim A. (1994):** Effects of salicylic acid on the plasma protein binding and pharmacokinetics of acid. *J. Pharm Sci*; 83: 883-6.
- Costa SH, (1998):** Commercial availability of misoprostol and induced abortion in Brazil. *International Journal of Gynecology and Obstetrics*, 63 (Supply): 5131-5139.
- Coutinho E and Mara H. (1991):** The contractile response of human uterus, fallopian tubes and ovary to prostaglandins *in vivo*. *Fertility & sterility*, 22; 539-543.
- Creinin MD, Wiebe E, Gold M, (1999):** Methotrexate and Misoprostol for early abortion in adnexent women *J. Pediatr. Adolesc Gynecol*, 12: 71-7.
- Crossland J (1980):** Prostaglandins, hormones and nucleotides. *Lewis Pharmacology*, p.387.
- Cunningham FG et al., (2005):** Preterm labor. In *Williams obstetrics*, 22 nd ed., pp-855-880.
- Cunningham FG, Gant NF, Leveno KJ, et al., (2001):** Conduct of normal labor and delivery. In: *Williams Obstetrics*. 21st ed. New York, NY: McGraw-Hill; 320-5.

- Cunningham FG, Mac Donald P, Leveno K, Gant N and Gilstrap L (2001):** Obstetrical hemorrhage in: Cunningham F, Mac Donald P, Leveno K, Gant K, Gilstrap L (eds). Williams Obstetrics 21th edition; 25: 619-671.
- Cunningham FG, Mac Donald PC (1989):** Dystocia due to soft tissue abnormalities of the reproductive tract. William's Obstetrics, 8th ed, pp 386.
- Currie MG and Needleman P. (1984):** Renal arachidonic acid metabolism. Ann. Rev. physiol, 46; 237-341.
- Danielsson RG, Marious L, Rodriguez A, Spur, BW Wong PY and Bygdeman M, (1999):** Comparison between oral and vaginal administration of misoprostol on uterine contractility. Obstet Gynaecol; 93: 2, 275:80.
- Dansereau J, Josh. AK, Helewa ME, et al., (1999):** Double-blind comparison of carbetocin versus oxytocin in prevention of uterine atony after cesarean section. Am J Obstet Gynecol, 180 (3pt1): 670-6.
- De Groot AN, Van Roosmalen, J, Van Dongen PW and Borm GF (1996):** A placebo-controlled trial of oral ergometrine to reduce postpartum hemorrhage. Acta Obstet Gynecol Scand, 75: 464-468.
- De Maeyer (1989):** Preventing and controlling iron deficiency anemia through primary health care, World Health Organization, Geneva.
- Decherney AH and Nathan Current (2003):** Obstetric and Gynecologic diagnosis and treatment L 9th Ed Lang medical books. pp365.
- Derman RJ, Kodkany BS, Gondar SS, Geller SE, Naik VA, Bellad MB, Patted SS, Patel A, Edlavitch SA, Hartwell T, Chakraborty H and Moss N (2006):** Oral misoprostol in preventing postpartum hemorrhage in resource-poor communities: a randomized controlled trial. The Lancet, Vol 368, Issue 9543, P 1248- 1253.
- Diab KM, Ramy AR and Yehia M (1999):** The use of rectal misoprostol as active pharmacological management of the third stage of labor. J Obstet Gynecol; 25(5): 327-32.
- Dimitrios S, Mastrogiannis D and Knuppel R. (1995):** Labor induction using methods that do not involve oxytocin. Clin Obstet and Gynecol; 38: 259-63.
- DMKG, (2003):** Misoprostol in the treatment of trigeminal neuralgia associated with multiple sclerosis J. Neurol, 250: 252.
- Donald I (1979):** Postpartum hemorrhage. Practical Obstetric Problems. 5th ed., 748.
- Duignan NM, Studd JWW, Hughes AO (1975):** Characteristics of normal labor in different racial groups. Br J Obstet Gynecol, 82-593-601.
- Egarter C and Husslein P. (1992):** Bailliere's Clinical Obstetrics and Gynecologys International Practice and Research. Prostaglandins: Baillier's Tindal, London, UK; 6: 756-769.
- Eggers TR, Fligner JR (1979):** Water intoxication and syntocinon. Obstet Gynecol, 19-59.
- Ekman, F, Forman A, Marchall K and U Lmsten U (1993):** Intravaginal versus intracervical applications of PGE₂ in viscous gel for cervical ripening and induction of labor at term in patients with unfavorable cervical state. Am J. Obstet Gynecol, 147: 657.

- Ekmekcioglu O, Demirci D, Yilmaz U and Tatlisn A, (1998):** Intraurethral misoprostol: a different agent in the treatment of erectile dysfunction, sexual dysfunction 1 (3): 161-164 doi: 10. 1046/J. 1460-2679.
- El-Refaey H and Rodeck C (2003):** Postpartum hemorrhage: a time for change. Oxford University Press, British Medical Bulletin, vol 67, PP: 205-217.
- Elbourne DR, Prendiville WJ, Carroli G, et al., (2002):** Prophylactic use of oxytocin in the third stage of labor (Cochrane review). In: The Cochrane library, Issue, 2. Oxford, UK: Update Soft Wave
- Elder MG (1992):** Baillieres clinical Obstetrics and Gynecology, international practice and research, vol 6/no 4: prostaglandins. Bailliere's Tindall; London, U.K.
- El-Refaey H (1995):** Misoprostol: Uterotonicity revealed or the place of misoprostol in the evaluation of human pregnant uterus. Fertility control reviews 4:19-21.
- El-Refaey H, O'Brien P, Morafa W and Walder J, (1997):** Use of misoprostol orally in the prevention of postpartum hemorrhage. Br. J.Obstet Gynecol, 104: 336-339.
- El-Refaey H, O'Brien P, Morafa W, Walder J, and Rodeck C, (1996):** Misoprostol for third stage of labor. The Lancet, 347-1257.
- El-Refaey H, O'Brien P, Morafa W and Walder J. (1997):** Use of misoprostol orally in the prevention of postpartum hemorrhage. Br J. Obstet Gynecol; 104:336-339.
- El-Refaey Nooh R, O'Brien P, Abdala M, Geary M, Walder J, Rodeck C (2000):** The misoprostol third stage of labor study: a randomized controlled comparison between orally administered misoprostol and standard management. Br. J.Obstet Gynecol; 107 (9): 1104-10.
- Shaff EA, Robert Dicenzo and Stephen L Fielding. (2005):** Comparison of misoprostol plasma concentration following buccal and sublingual administration. Contraception Vol 71, Issue. 1, pp, 22-25.
- Evans S, Mc Shane p (1985):** The efficacy of internal iliac artery ligation in Obstetric hemorrhage. Surg Gynecol Obstet 1985; 160-250.
- Fernando Arias (1993):** Postpartum complications in practical guide to high risk pregnancy and delivery, Ed. By Fernando Arias; published by Mosby year book Inc, 2nd ed., p 433-451.
- Flisiak R and Prokpowicz D. (1997):** Effect of misoprostol on the course of viral hepatitis B. Hepato-Gastroenterology; 44 (17): 1419-1425.
- Fonesca WVC, Alencer AJ, Mota FS and Coehlo HL, (1991):** Misoprostol and congenital malformation. The Lancet, 338; 56-59.
- Fong YF, Singh K and Prasad RNV (1998):** A comparative study using two dose regimens (200-400 mcg) of vaginal misoprostol for pre-operative cervical dilatation in the first trimester nulliparae. Br J Obstet Gynecol; 105: 413-417.
- Foote EF, Lee DR, Karim, A, Keune WF, Halstenson CD (1995):** Disposition of misoprostol and its active metabolite in patients with normal and impaired renal function. J. Clin Pharmacol; 35: 384-9.
-
-

- Frederic A, Spitz b, Timmerman D, Corremans A and Van Asshe A (1999):** Misoprostol compared with methylergometrine for the prevention of postpartum hemorrhage. A double blind randomized trial. *BJOG*; 106: 1066-70.
- Friedman MA (2001):** Manufacturer's warning regarding unapproved uses of misoprostol. *N Eng J Med*. 344:61.
- Fuchs AR, Hussein P, Fuchs F (1981):** Oxytocin and the initiation of human parturition and stimulation of prostaglandin production in the human deciduas by oxytocin. *Am J Obstet Gynecol*; 141: 694-6.
- Fuchs ARL, Fuchs F, Hussein P, Soloff MS and Fornsterm MJ (1982):** Pitocin receptors and human parturition: A dual role for oxytocin in the initiation of labor. *Sience* 251:1396.
- Ganesh A, Sammari T, Patel N, Habib A and Kiserud T (2001):** A randomized placebo controlled trial comparing effect of oral misoprostal and intravenous syntocinon on intravenous syntocinon on intraoperative blood loss during cesarean section. *Acta Obstet Gynecol*, 80: 245-50.
- Gemzell K, Marions, L, Rodriguez S, Wong P and Bygdeman M. (1999):** Comparison between oral and vaginal administration of misoprostol on uterine contractility *Obstet Gynecol*; 93: 275-80.
- Gilbert L, Porter W, Brown VA (1987):** Postpartum hemorrhage: a continuing problem. *Br J Obstet Gynecol*; 94-67
- Gilbert WM, Moore TR, Resnik R, et al., (1992):** Angiographic embolization in the management of hemorrhage complication of pregnancy. *Am J Obstet Gynecol* 1992; 166: 493.
- Giles H and Leff P (1988):** The biology and pharmacology of prostaglandins; 35: 277-300.
- Gilstrap LC, Cunningham F and Vandorsten J (2002):** Genital Tract lacerations and puerperal hematomas. *Operative Obstetrics*, 2nd ed;12: 223-239.
- Gilstrap LC, Cunningham F and Vandorsten J (2002):** Management of postpartum hemorrhage. In Seils A, Susan R, Nonjarim and Davis K(eds)*Operative Obstetrics* 2nd edition, 23:397-421.
- Gilstrap LC, Ramin SM, Yeomans E (1999):** Transverse imbrication sutures for postpartum hemorrhage. Personal communication.
- Gordon -Wright A and Elder M (1979):** PGE2 tablet used intravaginally for the induction of labor. *Br.J. Obstet Gynecol*; 86: 32-8.
- Gonzalesz JA, Carian SJ and Alrerson MW, (2001):** Out patient second trimester pregnancy termination. *Contraception*, 63 (2): 89-93.
- Gonzalez C.H. Marques M.J. Kim CA and Sugagama S.M. (1998):** Congenital abnormalities with misoprostol misuse in first trimester of pregnancy. *The Lancet*; 351, May 30: 1624-1627.
- Goszcz A, GrodzinsKa L, Kostka-Trbka E et al., (1998):** Treatment of peripheral vascular disease with misoprostol: a pilot study. *Methods find Exp. Clin Pharmacol*; 20(5): 439-45.
- Graham DY, Agrawal NM and Roth SH (1988):** A study on prevention of NSAIDs induced gastric ulcers with misoprostol. *The Lancet*; 2; 1277-1280.
-
-

- Graham DY, White RH, More Land LW. (1993):** Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. *Ann Intern Med*; 119:257.
- Greene KR, Drvota v and Vesterquist O (1990):** Pronounced reduction of invivo prostacyclin synthesis in humans by acetaminophen (paracetamol),. *Prostaglandins*; 37: 311-6.
- Grimes DA, Nada K (2006):** Magnesium sulfate tocolysis: Time to quit. *Obs. and Gyne.* 108 (4): 986-989.
- Grossland J (1980):** Prostaglandins, hormones and nucleotides, lewis pharmacology P. 387.
- Grover J, Mentakis E and Gross M (1997):** Three dimensional method for determination of amniotic fluid volume in intrauterine pockets, *Obstet Gynecol* 90, pp.1006-1010.
- Gulmezoglu AM (2000):** Prostaglandins for prevention of postpartum hemorrhage *Cochrane Database Syst. Rev*; (2) CD 000494.
- Gulmezoglu AM, Forna F, Villar J, Hofmeyr GJ (2004):** Prostaglandins for prevention of postpartum hemorrhage (Cochrane review). In: *The Cochrane library*, Issue 1. Oxford, UK: Update Software 2004.
- Gulmezoglu AM, Forna, F, Villar J and Hofmeyr GJ (2002):** Prostaglandins for prevention of postpartum hemorrhage (Cochrane Review). In: *The Cochrane Library*, Issue 2. Oxford, UK.
- Gulmezoglu AM, Villar J, Ngoc NT (2001):** WHO multicenter randomized trial of misoprostol in the management of the third stage of labor. *Lancet*; 358(9283):689-95.
- Gyton AC (1991):** The heart as a pump. *Text book of medical physiology*, 8th ed by Gyton A.C, published by W.B. Saunders CO., p.106.
- Hallek M, Dibly GA, Hurly TJ, Moise KJ (1991):** Transvaginal pressures pack for life threatening pelvic hemorrhage secondary to placenta accreta. *Obstet gynecol*; 78(5 pt 2): 938-40.
- Hamm J, Russel Z, Botha T and Carlan S. J (2005):** Buccal misoprostol to prevent hemorrhage cesarean delivery. A randomized trial *Am J.* volume 192, issue 5, P 1404-1406.
- Hansch E, Chitkarall, Mc Alpine J, Elsayed Y, Dake MD, Razavi MK (1999):** Pelvic arterial embolization for control of obstetric hemorrhage: a five- year experience. *Am J Obstet Gynecol*; 180 (6 pt1): 1454.
- Harmanci E, Ozakyol, A, Ozdemir N, Elbek O, Isik R, (1998):** Misoprostol has no favorable effect on bronchial hyper responsiveness in mild asthmatics *Allerg. Immunol (Paris)*:30: 298-300.
- Herabutya YO and Prasertsawat P,(1998):** Second trimester abortion using intravaginal misoprostol *Int. Gynecol Obstet*; 60: 2, 161.
- Herabutya YO, Chanrachakul B and Punyavachira P, (2001):** Second trimester pregnancy termination: a comparison of 600 and 800 mcg of intravaginal misoprostol. *J. Obstet Gynecol. Res.*, 27 (3): 125-8.
- Hewitt PE, Machin SJ (1998):** Massive blood transfusion. In: *ABC or transfusion*. London, England: BMJ Publishing;; 49-52.

- Hilbrands LB, Rischenvos J, Hene R and Hoitsma AJ, (1996):** Misoprostol and chronic renal transplant rejection. *Obstet Gynecol*, 105: 971.
- Hofmeyr GJ, Nikodem VC, de Jager M, Drakely A, (2001):** Side effects of oral misoprostol in the third stage of labor a randomized placebo controlled trial. *S Afr Med J*; 91 (5): 432-5.
- Hofmyer GJ, Nikodem VC, De Jager M and Gelbart BR (1998):** A randomized placebo controlled trial of oral misoprostol in the third stage of labor. *Br J Obstet Gynecol*, 105: 971-975.
- Hofmyer G, Walraven B, Maholwana Z, Alfrevic Z and Villar J (2005):** Misoprostol to treat postpartum hemorrhage: A systematic review, *BJOG* 112(5): 547-553.
- Horton EW and Poyser NL (1976):** Uterine luteolytic hormone. A physiological role of prostaglandin F₂α and. *Physio Rev.*; 56: 595-561.
- Howell RJS (1986):** Hemorrhage from the placental site. *Clinics in Obstetrics and Gynecology*, 13(3):633.
- Ivy LC, Grace WC, Ben CC and Chung HP (2003):** A study of co-treatment of nonsteroidal anti-inflammatory drugs (NSAIDs) with misoprostol for cervical priming before suction termination of first trimester pregnancy. *Contraception*; 67 (2): 101-5.
- Iwamura S and Kambegawa A (1981):** Determination of methylethergometrine and dihydroergonovine in biological fluids *J Pharm Dyn.* 4:275.
- Jackson KW, Albert JR, Schemmer GK et al., (2001):** A randomized controlled trial comparing oxytocin administration before and after placental delivery in the prevention of postpartum hemorrhage. *Am J Obstet Gynecol*; 185(4): 873-7.
- Jain JK, Mishell DR Jr (1994):** A comparison of intravaginal misoprostol with prostaglandin E₂ for termination of second-trimester pregnancy. *New England Journal of medicine*, 331: 290-293.
- Karim A, Rozek LF, Smith ME, Kowalis K KG, (1989):** Effects of food and antacid on oral absorption of misoprostol, a synthetics prostaglandin E₁ analogue. *Clin. Pharmacol*; 29: 439-43.
- Karim S and Sharma S (1971):** Therapeutic abortion and induction of labor by the intravagial administration of prostaglandin E₂ and F₂ α. *J Obstet Gynecol. Br. Commonw*, 78, 294-300.
- Karim S and Sharma S (1971):** Oral demonstration of prostaglandins for the induction of labor *BMJ*. 1: 260-7.
- Karim S, Trussel R, Patel R and Hillier K (1969):** Response of pregnant uterus to PGF₂ α induction of Labor *BMJ*. 4: 621.
- Karim A (1987):** Anti-ulcer prostaglandin misoprostol single and multiple dose pharmacokinetic profile. *Prostaglandin*; 33(suppl): 40-50.
- Keirse M, (1990):** Eicosanoids in Human Pregnancy and parturition. In: M Mitchell (ed): *Eicosanoids in reproduction*. Boca Raton, FL, CRC, Press1990; p. 199.
- Keirse M. (1993a):** Vaginal PG versus oxytocin for induction of labor. In: Enkin MW, Kerise MJ, Ren Freur MJ, Neilson IP (eds). *Pregnancy and child birth module*. Cochrane data base of systemic reviews. Review No. 04538. 3 April, 1992. Disc Issue 2-oxford, Update Software.

- Keirse M. (1993b):** Oral PGE₂ versus intravenous oxytocin for induction. In Enkin MW, Keirse MJ, Renfreur MJ, Neilson IP (eds): Pregnancy child birth module. Cochrane Database of Systemic Reviews. No 03327. 3 April. Disc Issue 2-Oxford, Update Software.
- Kim HJ, Kwak JY. (1996):** Effects of misoprostol on renal function and plasma endothelin-1 levels during early postoperative stage of living donor renal transplant recipients transplant Proc.28:1207-9.
- King JF, Flenady VJ, Papatsnis DN, Dekker GA, Carbonne B (2003):** Ca⁺⁺ channel blockers for inhibiting preterm labor, Cochrane data base of systematic reviews (online) (1): CD 002255.
- Kisser kE, Baskett TF (2002):** A ten year population based study of uterine rupture; Obstet Gynecol; 100 (4): 749-53.
- Koren G, Pastuszak A, Ito S (1998):** Drugs in pregnancy N Engl J.Med; 338: 1128.
- Kundodyiwa TW, Majko F and Ruskaniko S (2001):** Misoprostol versus oxytocin in the third stage of labor. Int J Gynecol Obstet, Vol 75, Issue 3, 235-241.
- Lam H, Tang OS, Lee CP, Ho PC (2004):** A pilot randomized comparison of sublingual misoprostol with syntometrine on blood loss in third stage of labor. Acta Obstet Gynecol Scand.; 83: 647-50.
- Lapaire O, Schnider MC, Stotz M, Surbek DV, Holzgreve W, and Hoesli IM (2006):** Oral misoprostol vs. intravenous oxytocin in reducing blood loss after emergency cesarean delivery. The International Journal of Gynecology and Obstetrics, Volume 95, Issue 1, p 2-7.
- Lamont RF, Morgan DJ, Logue M, Gordon H (2001):** A prospective randomized trial to compare the efficacy and safety of hemabate and syntometrine for the prevention of primary postpartum hemorrhage. Prostaglandins; 66: 203-10.
- Larry K, Robert E (1976):** Uterine anomalies. Obstet Gynecol; 47:427:429.
- Laurence DR and Bennet PN (1992):** Hypothalamic and pituitary hormones, sex hormones, contraception, uterus. Clinical Pharmacology. 7th ed. 1992; 610:613.
- Leake RD (1990):** Oxytocin in the initiation of labor. In: Carsten ME, Miller JD (eds). Uterine function. Molecular and cellular aspects. Plenum, New York: 361.
- Leung AS, Farmer RM, Leung EK, Medearis AL, Paul RH (1993):** Risk factors associated with uterine rupture during trial of labor after cesarean delivery: a case control study: Am J Obstet Gynecol; 168: 1358.
- Li XM, Wan J, Xu CF, Zhang Y, Fang L, Sh; ZJ, LI K (2004):** Misoprostol in labor induction of term pregnancy: a Meta analysis. Chin Med. J. (Engl). 177 (3): 449-52. Entrez Pub Med. Net.
- Liu HS, Chu TY, Change YR, Yu MH and Chen WH. (1999):** Interacervical misoprostol an effective method of labor induction. Int. J. Gynecol Obstet; 64: 1, 49-53.
- Lokugamage AU, Sullivan KR, Niculescu I, Tigere P, Onyangunga F, El-Refaey H, et al., (2002):** A randomized study comparing rectally administered misoprostol versus syntometrine combined with an oxytocin infusion for the cessation of primary postpartum hemorrhage. Acta Obstet Gynecol Scand; 80 (9): 825-9.
- Lokugamage AU, Paine M, Bassaw-Balroop K, Sullivan KR, El-Refaey H, Rodeck**

- CH. (2001):** Active management of the third stage of labor at cesarean section: a randomized controlled trial of misoprostol versus syntocinons Aust NZJ Obstet Gynecol, 41(4): 411-4.
- Lokugamage AU, Sullivan KR, Niculescu I, et al., (2001):** A randomized study comparing rectally administered misoprostol versus syntometrine combined with oxytocin infusion for the cessation of primary postpartum hemorrhage. Acta Obstet Gynecol Scand 2001 Sep; 80 (9): 835-9.
- Lumbiganon P, Hofmeyr J, Gumezoglu Am, Pmol A, Villar J (1999):** Misoprostol dose related shivering and pyrexia in the third stage of labor. WHO collaborative trial of misoprostol in the third stage of labor. BJOG;10(4):304-8.
- Lumbiganon P, Villar J, Piaggio G, Gulmezoglu AM, Adetoro L, Carroli G (2002):** Side effects of oral misoprostol during the first 24 hours after administration in the third stage of labor. BJOG, 109(11); 1222-6.
- Mackenzie I.Z (1987):** The clinical use of prostaglandins for cervical ripening and induction of labor-Ed K Hiller Land Caster: MTP press. In Eicosanoids and Reproduction, pp195-224.
- Mackenzie IZ (1994):** Labor induction including pregnancy termination for fetal anomaly. In: **James DK, Steer PJ, Weiner CP and Conik B (eds)** High Risk Pregnancy Management options, Philadelphia WB Saunders.
- Mackenzie IZ and Embrey MP (1977):** Cervical ripening with intravaginal PGE2 gel. Br. Med. J, 2, 1381-1384.
- Maier RC (1993):** Control of postpartum hemorrhage with uterine packing. Am J Obstet Gynecol: 169-317.
- Malhotra M, Sharma JB, Batras, Sharmas Murthy NS, Arora R (2002):** Maternal and perinatal outcome in various degrees of anemia. Int J Gynecol Obstet; 79: 93-100.
- Mantyla R and Kanto J (1981):** Clinical pharmacokinetics of methylergometrine(methylergonovine). Int J Clinical Pharmacol Toxiol. 19(9): 386.
- Mastrogiannis DS and Knuppel RA, (1995):** Misoprostol to induce labor. Clinical Obstet and Gynecol; 38-259.
- Mategrano VA and Gabay MP (2001):** Misoprostol in the prevention of postpartum hemorrhage. Ann pharmacother, 35 (12): 1648-52.
- McDonald S, Prendiville WJ, El bourne D (2002):** Prophylactic syntometrine versus oxytocin for delivery of the placenta (Cochrane Review). In: The Cochrane library, Issue 2. Oxford, UK: Update Soft ware. 2002.
- McKee RN, Wingrove FA, (1994):** Methods of treating damaged mucosal and epithelial tissues with misoprostol U.S. patent. 5, 510, 384.
- Meckstroth KR, Whiter AK, Bertisch S, Goldberg AB, and Darney PD (2006):** Misoprostol administered by epithelial routes: Drug absorption and uterine response. Obstet Gynecol 108 (pt 1): 582- 90.
- Meydanli MM, Caliskan E, Burak F, Narin M and Atmaca R. (2003):** Labor induction postpartum with 25 mcg vs. 50 mcg of intravaginal misoprostol. Int. J. Gynecol Obstet; 81 (3): 249-255.
- Michael R (2000):** Pharmacology of prostaglandin in drugs facts and comparison. St Louis, A Walters Kluwer Company. 1140-1141.
-

- Miller AWF and Mack DS (1974):** Induction of labor by extraamniotic prostaglandin. *J. Obstet Gynecol. Br. Commonw*, 81, 706-708.
- Mitchell S. Rein (2000):** Advances in uterine leiomyoma research: The progesterone hypothesis. Retrieved on 2007: 08-25.
- Mockenzie IZ and Embery MP (1978):** The influence of pre-induction vaginal prostaglandin E2 gel upon subsequent labor *Br. J. Obstet Gynecol*, 85, 657-661.
- Moran M, Mozes MF, Maddux, MS (1990):** Prevention of acute graft rejection by the prostaglandin E1 analogue misoprostol in renal -transplant recipients treated with cyclosporine prednisone. *N. Engl. J. Med*; 322: 1183-8.
- Mousa HA, Alfirevic Z (2003):** Treatment for primary postpartum hemorrhage. *Cochrane Database Syst Rev*; (1): CD003249.
- Mousa HA, Alfirevic Z, (2004):** Treatment for primary postpartum haemorrhage (Cochrane Review). In: *The Cochrane Library*. Eds Chichester (UK): John Wiley & Sons, Ltd; 2004. Issue 1.
- Munthal J and Moodley J (2001):** The use of misoprostol for midtrimester therapeutic termination of pregnancy. *Trop Doct*; 31 (9): 157-61.
- Muzonzini G. (2004):** Buccal or sublingual misoprostol for cervical ripening and induction of labor. *Cochrane Database of Systematic Reviews*, Issue 4.
- Nadler JL, Natarj and R and Stern N. (1987):** Specific action of the lipooxygenase pathway in mediating angiotensin II induced aldosterone synthesis in isolated adrenal glomerulosa cells. *J Clin. Inves*, 80: 1763-1769.
- Naftalin, Nicholas J.M.P, McKay, Goldberg and Alan H (1977):** The effects of halothane on pregnant and nonpregnant human myometrium. *Anesthesiology*, 46(1); 15-19.
- Newton ER (2005):** preterm labor, preterm premature rupture of membranes, and chorioamnionitis. *Clin perinatal* 2005 Sep; 32 (3): 571-600.
- Ng PS., Chan AS, Sin WK, Tang LC, Cheung KS, Yen PM, (2001):** A multicenter randomized controlled trial of oral misoprostol and IM syntometrine in the management of the third stage of labor. *Hum Reprod*, 16 (1): 31-35.
- Ngai SW, Chan YM, Lui KL and Ho RC (1997):** Oral misoprostol for cervical priming in non-pregnant women. *Hum Reproduction*, 12: 2373-5.
- Nicholson PA, Karim A, Smith M (1990):** Pharmacokinetics of misoprostol in the elderly in patients with renal failure and which coadministration with NSAIDs or antipyrin, propranolol or diazepam. *J. Rheumatol Suppl*; 20:33-7.
- Nordstrom, Fogelstam K, Friedman G, Larsson A and Rydhstroem H (1997):** Routine oxytocin in the third stage of labor. *Br J Obstet Gynecol*; 104: 781-786.
- Norman J, Thong K and Baird D (1991):** Uterine contractility and induction of abortion in early pregnancy by misoprostol and mifepristone. *Lancet* 338: 1233. Cited in El-Refaey H. 1995.
- Nugterene DH, Berthuis RK and Van Drop DA (1966):** The enzymatic conversion of all-cis, 8, 11, 14-eicosanoic acid into prostaglandin E1-*Recueil des travaux chimiques des pays Bas* 85: 405-419.
-
-

- Oboro VO, Tabowei TO (2003):** A randomized controlled trial of misoprostol versus oxytocin in the active management of the third stage of labor. *J Obstet Gynecol*, 23(1): 13-6.
- O'Brien P, El-Refaey H, Gordon A, Geary M, Rodeck CH, (1998):** Rectally administration misoprostol for the treatment of postpartum hemorrhage unresponsive to oxytocin and ergometrine : a descriptive study *Obstet Gynecol*; 92 (2): 212-4.
- O'Brien W (1995):** The role of prostaglandins in labor and delivery. In: Kupple AR (ed): *Clin perinatol* 22,973-984. Complicated labor and delivery. Philadelphia, WB Saunders.
- O'Brien WF and Cefalo RC (1996):** Labor and delivery. In: Gabbe R(eds) *Obstetrics- Normal and problem pregnancies*, Third edition. Churchill Livingstone, London, UK; pp371
- O'Brien, P, El-Refaey H, Gordon A, Geory M and Rodek CH, (1998):** Rectally administered misoprostol for the tretament of postpartum hemorrhage responsive to oxytocin and ergometrine: a descriptive study.*Obstet Gynecol*; 92 (2): 212-4.
- Oei PL, Chua S, Tan L, Ratnam SS, Arul Kumaran S (1998):** Arterial embolization for bleeding hysterectomy for intractable postpartum hemorrhage. *Int J Gynecol Obstet*; 62(1): 83.
- O'leary JA (1995):** Uterine artery ligation in the control of post cesarean hemorrhage. *J Reprod Med*; 40 (3): 189-93.
- Olson D and Zakart T (1993):** Intrauterine tissue prostaglandin Synthesis: Regulatory mechanisms. *Seminars Reprod Endocrine*; 11: 234.
- Orga S, Kirton K, Tomasi T and Lippes G. (1994):** Prostaglandins in human fallopian tube fertile and steril; 25: 250-255.
- Padden MO (1999):** HELLP syndrome: recognition and perinatal management *American family physician* 60 (3): 829: 36-839.
- Pena JCG, (1995):** Misoprostol for induction of labor (letter). *Am. J. Obstet Gynecol*; (174): 797.
- Phelan JP, Ahn MO, Smith CV, Rutherford SE and Anderson (1987):** Amniotic fluid index measurements during pregnancy, *J Reprod Med* 32, pp.601-604.
- Phelan k, Mosholder A, LU S (2003):** Lithium interaction with COX2 inhibits rofecoxib and celecoxib and other NSAIDS "J Clin Psychiatry 64 (11): 1328-34.
- Physicians' Desk Reference, 44th edition (1990):** Publisher EDWARD BARNHART.
- Pierre F, Mesnard L, Body G (1992):** For a systematic policy of i.v. oxytocin induced placenta deliveries in a unit where a fairly active management of third stage of labor is yet applied: results of a controlled trial. *Eur J Obstet Gynecol Reprod. Biol* 1992 Jan 31; 43(2): 131-5.
- Plauche WC (1992):** Peripartum hysterectomy. In: Plauche WC, Morrison JC, O'Sullivan MJ, eds. *Surgical Obstetrics*, Philadelphia: WB Saunders; 447-65.
- Plauche WC (1991):** Surgical problems involving the pregnant uterus: uterine inversion, uterine rupture and leiomyomas. In: Plauche WC, Morrison JC, O'Sullvian MJ (eds), *surgical Obstetrics*. Philadelphia: WB Saunders, 1991.

- Pongsatha S, Tongsong T, (2001):** Second trimester pregnancy termination with 800 mcg vaginal misoprostol. *J. Med. Assoc Thai*, 84 (6): 859-63.
- Poole-Wilson PA, Kirwan BA, Vokoz, de Brouwer S, Van Dalen FJ, Lubsen J (2006):** Safety of nifedipine GITS in stable angina "Action Trial" *Cardiovas Drugs* 20 (1): 45-54.
- Prendiville WJ, El bourne D, Me Donald S (2002):** Active versus expectant management in the third stage of labor (Cochrane review). In: the Cochrane library, Issues. Oxford, UK: Update software 2002.
- Prendiville WJ, Elbourne D, McDonald S (2000):** Active versus expectant Management in the third stage of labor, *Cochrane Data base Syst Rev* 2000; (2) CD000007.
- Price N, B-Lynch C (2005):** Technical description of the B-Lynch brace suture for treatment of massive postpartum hemorrhage. *Int J Fertil Womens Med*; 50(4): 148-63.
- Quiroga Diaz R, Esparza Arechiga M, Batiza Resendiz V, Coronado Lopez, Hernandex Ayup S, and Martinet Curervo J (2002):** Vaginal misoprostol in the prevention of postpartum hemorrhage. *Ginecol Obstet Mex*, 70: 572-5.
- Rainford KD, James C, Hunt RH, et al., (1992):** Effects of misoprostol on the pharmacokinetics of indomethacin in human volunteers. *Clin Pharmacol*; 15: 415-21.
- Rath W and Heyl W (1996):** Prostaglandin induced labor is theprostaglandin E2 gel. *Geburt shiefe frauenheikd*; 536-41.
- Ratnam SS, Viegas O.A.C. and Singh K. (1989):** Magnitude and causes of maternal mortality as bass for its prevention. Zurich. Switzer land: ott publishers; 80: 90. Quoted from **O'Brien P, El-Refaey H, Gordon A, Geary M and Rodeck C.:** Rectally administered misoprostol for the treatment of postpartum hemorrhage unresponsive to oxytocin and ergometrine: A descriptive study *Obstet Gynecol*, 92:212-214.
- RCOG Greentop Guidelines, No 27(2005):** Placenta praevia and placenta praevia accreta: Diagnosis and management.
- Rock Head C, Fletcher H, Reid M and Morgan O. (2003):** A comparison of two methods of labor induction with vaginal misoprostol. *Int. Gynecol. Obstet* ; 80(3): 271-7.
- Rogers J, Wood J, Mc Candlish R, et al (1998):** Active versus expectant management of third stage of labor: the Hiching brooke randomized controlled Trial. *Lancet* 7; 351(9104): 693-9.
- Roman H, Robillard PY, Verspyck E, Hulsey TC, Marpeaul, Barau G (2004):** Obstetric and neonatal out comes in grand multiparity. *Obstet Gynecol* 2004; 103: 1294-9.
- Roosendal G, Lafeber F (2007):** Prophylactic treatment for prevention of joint disease in hemophilia accost versus benefit. *N Engl. Med.* 2007 9, 357(9): 603-5.
- Sadler JE (1994):** A revised Classification of vonWillbrand disease thromb Hemost; 71: 520-5.
-
-

- Sanchez-Ramos L, Kaumitz AM and Delke I, (2002):** Labor induction with 25 mcg versus 50 mcg intravaginal misoprostol: A systematic review. *Obstet Gynecol*; 99 (1): 145-51.
- Sandberg F., Ingelman- sundberg A., Ryden G et al. (1968):** The absorption of tritium-labeled prostaglandin E1 from the vagina of non pregnant women. *Acta Obstet Gynecol Scand*, 47: 22-26.
- Sanghvi H, Wiknjosastro G, Chanpoing G, Fishel J and Ahmed S (2004):** Prevention of postpartum hemorrhage: West Java, Indonesia, Baltimore, Maryland, JHIPBGO. Maternal and Neonatal Health Program.
- Saxena P, Salhan S and Sarda N, (2003):** Role of sublingual misoprostol for cervical ripening prior to vacuum aspiration in first trimester interruption of pregnancy. *Contraception*, 67: 213.
- Schaff EA, Permesta U and Fong YF (2000):** Vaginal misoprostol 1, 2 or 3 days after mifepristone affects safety and effectiveness. *Arch Fam Med*; 3:772-8.
- Schoenhard G, Oppermann J, Kohn FE. (1985):** Meta-bolism and pharmacokinetics studies of misoprostol. *Dig. Dis. Sci*; 30 (11 suppl): 1265-8.
- Serror J, Allouche C, El-Haik S (2005):** Use of Sungstaken-Blakemor tube in massive postpartum hemorrhage: a series of 17 cases. *Acta Obstet Gynecol Scand*; 84 (7): 660-4.
- Shojai R, Piechon L, D'Ercole C, Boubil L, Ponties L, Ponties JE, (2001):** Rectal administration of misoprostol for delivery induced hemorrhage. Preliminary study. *J. Gynecol Obstet Biol. Reprod (Paris)* 30 (6): 572-5.
- Shuurmans N, Mackinnonk, Lane C, Etches D (2000):** Prevention and management of postpartum hemorrhage. *J Obstet Gynecol Can* 2000; 22(4): 27-81.
- Silverstein FE, Graham DY, Senior JR. (1995):** Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal antiinflammatory drugs *Ann inter Med*; 123:241.
- Sirimai, Kiriwat O, Neungton S and Suvanichchat S (2002):** Misoprostol use for therapeutic abortion Siriraj Hospital, *J. Med. Assoc. Thai*, 85 (4): 416-23.
- Smith C, Rayburn W and Miller A (1994):** Intra vaginal Prostaglandin E2 for cervical ripening and initiation of labor: Comparison of a multidose gel and single, controlled release pessary. *J. Reprod Med*. 39: 381-6.
- Smith J (2006):** Postpartum hemorrhage. Department of Obstetrics and Gynecology; United Arab Emirates University, www.E.medicine.com.
- Smith WG, Thompson JM, Kowaliski DL, McKearn JP (1996):** Inhaled misoprostol blocks guinea pig antigen produced bronchospasm and air way inflammations. *Am. J. Respir Crit Care Med*. 154: 295-9.
- Society of Obstetricians and Gynecologists of Canada (2002):** Advances in Labor and Risk Management (ALARM) case Manual. 9thed. Ottawa, Ontario, Canada: Society of Obstetricians and Gynecologists of Canada.
- Song J (2000):** Use of misoprostal in Obstetrics & Gynecology. Review article *Dbstet Gynecol. Survey* 55 (8): 503-510.
- Speroff L and Fritz MA. (2005):** Clinical gynecologic endocrinology and infertility (text book); Lippincott William&Wilkins, Philadelphia. Seventh edition, pp. 289-305.
-
-

- Stainsby D, Maclellan S, Hamilton PJ (2000):** Management of massive blood loss: a template guideline. *Br J Anaesth* 2000 Sep; 85(3): 487-91.
- Stanco LM, Schrimmer DB, Paull RH, Mishell DR. Jr (1993):** Emergency peripartum hysterectomy and associated risk factors. *Am J Obstet Gynecol*; 168 (3pt1): 879-83.
- Stevens W, Koene H, Zwaginga JJ, Vrengdenhil G (2006):** Chronic idiopathic thrombocytopenic purpura the Netherlands Journal of medicine. 64 (10):
- Stobie-Hayes KM, and Fewell E (1996):** Influence of pregnancy on the febrile response to intracerebroventricular administration of PGE1 in rats. *Appl. Physical*; 81: 1312-15.
- Surbek DV, Fehr PM, Hosli I, Holzgrer W. (1999):** Oral misoprostol for third stage of labor: a randomized placebo controlled trial. *Obstet Gynecol*; 94 (2): 255-8.
- Tammy S, Gevsten Feld D and Deborah A (2001):** Rectal misoprostol versus intravenous oxytocin for the prevention of postpartum hemorrhage after vaginal delivery. *Am J Obstet Gynecol*; 185: 878-82.
- Tang OS, Schweer H, Seyberth NW, Lee SWH and Ho PC (2002):** Pharmacokinetics of different routes and administration of misoprostol. *Hum Reprod* 17, 332-336.
- Toppozada M, Baird DT, Grimes DA and Van Look P. (1995):** Termination of pregnancy after 14 weeks, Modern methods of inducing abortion. Oxford, U.K. Blackwell Science; 70-95.
- Toppozada M, El-Basset MA and El-Rahman HA, (1981):** Control of intractable postpartum hemorrhage by 15-methyl prostaglandin F₂. *Obstet Gynecol*; 58: 327-330.
- Templeton A. (1998):** Misoprostol for all?? *Br. J. Obstet Gynecol*; 105: 937-939.
- Todd CS, Soler M, Castleman L, Rogers MK, Blumenthal PD (2002):** Buccal misoprostol as cervical preparation for second trimester pregnancy termination. *Contraception* 65, pp 415-418.
- Torre S, Gison GJ, Flares S, Curet LB, Qualts CE and Rayburn W, (2001):** Is high dose misoprostol able to lower the incidence of cesarean section? A randomized controlled trial. *J. Matern Fetal Med*, 10 (2): 85-90.
- Turnbull AC and Anderson ABM (1968):** Induction of labor. Part 2. Intravenous oxytocin infusion. *J. Obstet Gynecol. Br. Commonw.* 75, 24-31.
- Ueda K, Sato A, No Kano H and Iwaya T (1980):** Natural prostaglandins disadvantages. *J Pediatr*, 97: 334.
- Usui R, Matsubara S, ohkudi A et al., (2007):** Fetal heart pattern reflecting the severity of placental abruption: 10. 1007/ 500404-007-0471-9.
- Villar J, Gulmezoglu AM, Hofmeyr GJ, Forna F (2002):** Systematic review of randomized controlled trials of misoprostol to prevent postpartum hemorrhage. *Obstet Gynecol* ;100:1301-12.
- Vimala J, Mittal S, Kumar S, Dadhwal V and Mehta S (2004):** Sublingual misoprostol versus methylergometrine for active management of the third stage of labor. *Int J Gynecol Obstet*; 87, 1-5.
- Vimala N, Mittal S, Kumar S (2006):** Sublingual misoprostol versus oxytocin infusion to reduced blood loss at cesarean section. *Int J Gynecol Obstet*, 92: 106-10.
-
-

- Walder J, (1997):** Misoprostol preventing postpartum hemorrhage. *Mod Midwife*, 7 (9): 23-7.
- Walley RL, Wilson JB, Crane JM, Mathews K, Sawyer E, Hutchens D (2000):** A double blind placebo controlled randomized trial of misoprostol and oxytocin in management of third stage of labor. *Br. J.Obstet Gynecol*; 107 (9): 111-5.
- Weckstein LN, Masserman JS, Garite TJ (1987):** Placenta accreta: a problem of increasing clinical significance. *Obstet Gynecol*; 69: 480.
- Weir MR, Klassen DK and Hall PS (1991):** Minimization of indomethacin-induced reduction in renal function by misoprostol *J. Clin. Pharmacol*; 31: 729-735.
- Weinstein L (1982):** Syndrome of haemolysis, elevated liver enzymes, and low platelet count: a severe consequence of hypertension in pregnancy. *Am. J. Obstet. Gynecol* 142(2): 159-67.
- Whitefield CR (1988):** Benign tumors of the uterus. *Dewhurst's Text Book of Obstetrics and Gynecology for Postgraduates*, 4th ed, pp 732.
- WHO (World Health Organization) (2005):** Attending to 136 million births, every year: make every mother and child count: The World Report; 2005, WHO, Geneva, Switzerland, 62-63.
- WHO (World Health Organization) (1990):** The prevention and management of postpartum hemorrhage. Report of a technical working Group. Geneva 3-6 July 1989. World Health Organization, Maternal and Child Health 09.7.Geneva: WHO.
- Wilson NH and Jones RL (1985):** Prostaglandin endoperoxide and thromboxane A2 analog. *Prostaglandin thromboxane Res.*; 14: 393-425.
- Wilson RF, Mammern E, Walt A (1971):** Eight years of experience with massive blood transfusions. *J trauma*; 11: 275.
- Wing D, Jones M, Rahall A, Goodwin T and Paul R (1995):** A comparison of misoprostol and prostaglandin E2 gel for preinduction cervical ripening and labor induction *Am J. Obstet Gynecol*; 172: 1804-10.
- Wing DA, Ham D and Paul RH, (1999):** A comparison of orally administered misoprostol with vaginally administered misoprostol for cervical ripening and labor induction; *Am. J.Obstet Gynecol*; 180: 5, 1155-60.
- Witter F, Rocco L and Johnson (1992):** A randomized trial of prostaglandin E2 in a controlled-release vaginal pessary for cervical ripening at term. *Am. J. Obstet Gynecol*; 166: 830-4.
- Wittich AC, Salminen ER, Hardin EL, Desantis RA (1996):** Uterine packing in the combined management of obstetrical hemorrhage (case report) *mild med*; 161(3): 180.
- WHO (World Health Organization) (1991):** The global picture. The causes of maternal death. In: Abouzahar C, Royston E, eds. *maternal mortality: A global fact book*. World Health Organization, Geneva, 7-11.
- WHO (World Health Organization) (1994):** Maternal Health and safe mother hood programme World Health Organization partograph in management of labor. *Lancet*, 343: 1399-404.
- Wray S (1993):** Uterine Contraction and physiological mechanism of modulation .*Am J Physiol* 264: C1-C18.
-
-

- Xiao (2003):** Misoprostol and mifepristone combine to open the emergency contraception window. *Contraception*, 68: 477.
- Xiong X, Buekens P, Alexander S, et al., (2000):** Anemia during pregnancy and birth outcome: a meta-analysis. *Am J Perinatal* 2000; 17(3): 137-46.
- Yamashita Y, Takahashi M, Ito M, Okamura H (1991):** Transcatheter arterial embolization in the management of postpartum hemorrhage due to genital tract injury. *Obstet Gynecol*; 77: 160.
- Yaung CW, Lee SH, Kim YS and Chang YS, (1996):** Prevention of post transplant peptic ulcer by misoprostol *Nephron*; 74 (1): 131-135.
- Yulzari-Roll V, Hod M and Bar J. (2002):** New developments in labor induction. *Harefuah*; 141 (4): 369-73, 408.
- Zaki ZM, Bahar AM, Ali ME, Albar HA, Gerais MA (1998):** Risk factors and morbidity in patients with placenta previa accreta compared to placenta previa non accrete. *Acta Obstet Gynecol Scand*; 44: 835.
- Zelop CM, HarLow BL, Firgoletto FD Jr, Safon LE, Saltzman D (1993):** Emergency peripartum hysterectomy. *Am J Obstet Gynecol*; 168: 1443.
- Zhao Y, Li X and Peng Y (1998):** Clinical study on reduction of postpartum bleeding in cesarean section by misoprostol. *Zhonghua Fu Chan Ke Za Zhi*, 33 (7): 40.3-5.
- Zieman M, Fong, SK, Benowitz NL, Banskter D and Darney PD, (1997):** Absorption kinetic of misoprostol with oral or vaginal administration. *Obstet Gynecol*; 90 (1): 88-92.
- Zuberi NF, Durocher J, Sikander R, Baber N, Blum J and Walraven G (2008):** Misoprostol in addition to routine treatment of postpartum hemorrhage: A hospital based randomized controlled trial. *BMC Pregnancy and Childbirth*, 8:40. On line at: [www. Biomedcentral.com](http://www.Biomedcentral.com)